Answers are grounded in this paper and cite their sources.
Background Hepatosplenic T-cell lymphoma (HSTCL) is a rare and highly aggressive mature T-cell neoplasm characterized by preferential involvement of the spleen, liver, and bone marrow. Conventional chemotherapy frequently results in primary refractory disease or short-lived responses, and effective salvage strategies remain limited. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a potentially curative approach in eligible patients who achieve adequate disease control. Case presentation A 21-year-old man presented with severe cytopenias, massive splenomegaly, and bone marrow involvement. Expert pathological review demonstrated predominantly sinusoidal infiltration by cytotoxic T cells expressing CD2, CD3, CD5, CD7, CD8, granzyme B, and TIA-1, supporting the diagnosis of HSTCL. The patient showed no meaningful response to CHOEP and subsequently developed progressive disease following Hyper-CVAD. Venetoclax was therefore incorporated into an ICE chemotherapy backbone. Venetoclax was administered at 800 mg once daily for 10 days. Following the first cycle of venetoclax plus ICE (Ven-ICE), splenic craniocaudal length decreased from approximately 25 cm to 14 cm. After two cycles, the reduction in disease burden was maintained, and the patient proceeded to allo-HSCT from a fully HLA-matched related donor. At approximately 30 days after allo-HSCT, blood counts had substantially recovered, with a white blood cell count of 4.65 × 10 9 /L, absolute neutrophil count of 3.15 × 10 9 /L, hemoglobin of 11.4 g/dL, platelet count of 135 × 10 9 /L, and LDH of 284 U/L. Bone marrow examination showed no morphologic evidence of recurrent HSTCL, and flow cytometry detected no clonal T-cell population. At the most recent follow-up, approximately 3.5 months after allo-HSCT, the patient remained in remission, with no clinical evidence of acute GVHD. Conclusion Ven-ICE provided rapid disease reduction after failure of CHOEP and Hyper-CVAD and created a therapeutic window for subsequent allo-HSCT in this patient with chemorefractory HSTCL. Because ICE has established activity in HSTCL and BCL-2 dependence was not assessed, the independent contribution of venetoclax cannot be determined. This case supports further investigation of venetoclax-containing combination strategies as a potential bridge to transplantation in refractory HSTCL.
No takes yet. Share an insight, caveat, or question.
Zorlu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: